Audentes Therapeutics Inc (BOLD) Given Average Recommendation of “Buy” by Analysts

Audentes Therapeutics Inc (NASDAQ:BOLD) has been assigned a consensus recommendation of “Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $41.66.

A number of equities analysts have issued reports on BOLD shares. BidaskClub upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. ValuEngine upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $33.00 price objective on shares of Audentes Therapeutics in a research report on Friday, January 11th. Finally, Mizuho restated a “buy” rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a research report on Friday, February 1st.

In related news, CEO Matthew R. Patterson sold 21,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.00, for a total transaction of $630,000.00. Following the sale, the chief executive officer now owns 135,700 shares of the company’s stock, valued at $4,071,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total transaction of $300,600.00. Following the sale, the vice president now directly owns 28,236 shares in the company, valued at approximately $848,774.16. The disclosure for this sale can be found here. Insiders have sold a total of 51,000 shares of company stock worth $1,650,600 in the last ninety days. Insiders own 6.60% of the company’s stock.

Large investors have recently bought and sold shares of the stock. NumerixS Investment Technologies Inc boosted its stake in Audentes Therapeutics by 1,200.0% during the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 1,200 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in Audentes Therapeutics during the fourth quarter worth about $92,000. Great West Life Assurance Co. Can boosted its stake in Audentes Therapeutics by 96.0% during the fourth quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,315 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Audentes Therapeutics by 46.1% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 1,983 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 1,700 shares in the last quarter. 97.40% of the stock is currently owned by institutional investors and hedge funds.

Shares of BOLD stock traded up $0.74 during mid-day trading on Wednesday, reaching $37.79. The stock had a trading volume of 981,500 shares, compared to its average volume of 539,841. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $46.18. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.11 and a beta of 1.85.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). During the same quarter in the previous year, the firm posted ($0.74) EPS. On average, research analysts expect that Audentes Therapeutics will post -3.8 EPS for the current fiscal year.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Put Option

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.